The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...
Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...
Eli Lilly is taking the HRSA to court after the latter allegedly blocked the pharma's plan on the manner of offering ...
The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that ...
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...
Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we ...
California is poised to pass a ballot measure aimed at imposing 340B spending restrictions for certain healthcare entities participating in the ...
Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson with an Outperform rating and $190 price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback